Charles Russell Speechlys was pleased to act for Cogenpower plc (“Cogenpower”) on its admission to AIM which completed on 12 February 2015.

Travers Smith corporate finance partner Richard Spedding and corporate finance senior associate Mark Anderson have advised Liberum Capital Limited (as nominated adviser and sole bookrunner) to Shield Therapeutics plc (“Shield Therapeutics”), on its £162 million IPO.

The IPO involved the conditional placing and subscription of £32.5 million of new ordinary shares and the issue of warrants to subscribe for ordinary shares, which, if exercised in full, would generate an additional £17.5 million of gross proceeds for Shield Therapeutics.

Taylor Wessing has represented Tritax Big Box REIT plc on its recent placing, open offer and offer for subscription, raising £200 million in total, with demand significantly in excess of that amount. Jefferies International Limited represented Tritax as Sponsor, Sole Global Co-ordinator, Bookrunner and also as joint financial adviser with Akur Limited. Goodwin Procter acted as US counsel to Tritax.

The team was led by client relationship partner William Belcher, with support from Katie Bennett, James Homan and Joe Davis.

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Travers Smith Corporate partner Richard Spedding and senior counsel Dan McNamee  have advised Canaccord Genuity and Investec, as joint bookrunners, on the block trade by Julian Dunkerton of shares held in SuperGroup Plc.

Julian Dunkerton, one of the founders of SuperGroup and its Product & Brand Director, sold 4.0 million ordinary shares in the company, representing approximately 4.9 per cent. of its issued share capital. The Placing Shares were placed at a price of 1,200 pence.

Mylan N.V. has announced a recommended public offer to the shareholders of Meda AB (publ) to tender all their shares in Meda to Mylan. The total offer consideration consists of a combination of cash and Mylan ordinary shares. At announcement, the total value of the offer for all Meda shares, including Meda net debt, is approximately SEK 83.6 billion or USD 9.9 billion.
 

On 10 February 2016 Scandinavian Tobacco Group, the tobacco producer, was admitted to trading and official listing on Nasdaq Copenhagen. Plesner acted as legal advisor to JP Morgan, Nordea, Deutsche Bank and Carnegie in connection with the listing.

NautaDutilh advised Mylan in its recommended public offer for pharmaceuticals company Meda. The offer consideration consists of a combination of cash and Mylan ordinary shares with a value at announcement of SEK 165 per Meda share. The total enterprise value of the offer for all Meda shares is approximately SEK 83.6 billion or USD 9.9 billion.

Noerr has advised ODDO SEYDLER BANK AG on the initial public offering of B.R.A.I.N. Biotechnology Research and Information Network AG. ODDO SEYDLER coordinated the transaction as the sole global coordinator and sole bookrunner. BRAIN AG is the first biotechnology company to go public on a German stock exchange in ten years.

Osborne Clarke is advising Xnext in its equity crowdfunding campaign launched on the Equinvest platform, in cooperation with Backtowork24 – Gruppo 24 Ore.